SK-Pharma’s division of ‘Infection Prevention’ is primarily focusing on allocating preventative solutions to mitigate infections in; hospitals,clinics and special healthcare units. We strive to minimize the prevalence of hospitalizations and complications of MRSA as well as other clinically acquired resistant bacterial infections. According to the CDC, in 2002, Healthcare Acquired Infections (HAI’S) caused 1.7 million hospitalization and 99,000 associated deaths In the US alone, where in Israel, according to the Ministry of Health, it is known that more than 4000 patients are dying a year because of various of complications of HAI’s. SK-Pharma’s mission is to reduce the number of HAI’s infections and consequentially deaths to the minimal possible, by introducing healthcare products and promoting educationto embrace basic and impactable solutions.